Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03676725 · ClinicalTrials.gov registry record · Early Phase 1
Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD
A Early Phase 1 study, sponsored by PhenoSolve.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
NCT03676725: Completed Early Phase 1 study, sponsored by PhenoSolve.
NCT03676725 is a Early Phase 1 study that has completed, run by PhenoSolve. The registered enrollment target is 90 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03676725, a Early Phase 1 study, has completed, sponsored by PhenoSolve.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
Primary Outcome
Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 10 (very intense) scale before and after application of Lidocaine. Lidocaine effectiveness was quantitated as the reduction or elimination of taste by lidocaine compared to taste scores reported before lidocaine. For each of the four before/after pairs, the change in taste intensity was calculated, a weighted average score was computed. Incorrectly identified tastes were excluded. Scores of a reduction in taste
Interventions
- DRUG Lidocaine gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-08-14 |
| Est. Completion | 2020-03-01 |
| Phase | Early Phase 1 |
What the finished NCT03676725 record still lists
NCT03676725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 1 intervention - of which Lidocaine gel is the first listed.
NCT03676725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03676725 about?
NCT03676725 is a clinical study titled "Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD". This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
What is the current status of trial NCT03676725?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2019-08-14. Estimated completion is 2020-03-01.
What interventions are being tested in trial NCT03676725?
The interventions under investigation include: Lidocaine gel (DRUG).
Who is sponsoring clinical trial NCT03676725?
This trial is sponsored by PhenoSolve, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03676725's enrollment target sits among peer trials
90 233rd of 2000 higher than 1,753 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI